Insider Selling: InspireMD (NYSE:NSPR) Insider Sells 5,132 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 5,132 shares of InspireMD stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.46, for a total transaction of $12,624.72. Following the completion of the transaction, the insider directly owned 1,104,601 shares of the company’s stock, valued at approximately $2,717,318.46. This trade represents a 0.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Trading Up 3.0%

Shares of NSPR traded up $0.03 during midday trading on Thursday, reaching $1.03. The stock had a trading volume of 160,140 shares, compared to its average volume of 182,457. The firm has a 50 day simple moving average of $1.40 and a 200-day simple moving average of $1.68. InspireMD, Inc. has a one year low of $0.97 and a one year high of $2.93. The firm has a market cap of $48.24 million, a PE ratio of -1.37 and a beta of 0.82.

Institutional Trading of InspireMD

Several hedge funds and other institutional investors have recently bought and sold shares of NSPR. Renaissance Technologies LLC acquired a new stake in InspireMD in the 1st quarter worth about $29,000. XTX Topco Ltd acquired a new stake in InspireMD in the 4th quarter worth about $30,000. Virtu Financial LLC acquired a new stake in InspireMD in the 4th quarter worth about $31,000. Creative Planning acquired a new stake in InspireMD in the 2nd quarter worth about $44,000. Finally, Legato Capital Management LLC acquired a new stake in InspireMD in the 4th quarter worth about $48,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

More InspireMD News

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on NSPR shares. Loop Capital set a $5.00 price target on shares of InspireMD in a research note on Tuesday, February 24th. Lake Street Capital set a $4.00 price objective on InspireMD in a report on Monday, May 4th. Maxim Group began coverage on InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Finally, Piper Sandler reissued an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, InspireMD currently has a consensus rating of “Buy” and a consensus target price of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.